Adefovir Dipivoxil

阿德福韦酯

Report date: 2022/12/07 17:15:33
NME

Base Information

Drug NameAdefovir Dipivoxil
Drug Alias NameAdefovir Pivoxil阿德福韦二匹伏酯阿德福韦地匹福酯阿地福韦酯阿地福韦双酯 +[14] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionImmunostimulantsHBV DNA Polymerase inhibitorsReverse transcriptase inhibitors
TargetsReverse transcriptaseHBV DNA Polymerase
Therapy Area/IndicationsHepatitisCytomegalovirus InfectionsHepatitis B, Chronic +[6] 
Global Approved IndicationsHepatitis B, ChronicHepatitis B
Approved Indications in ChinaHepatitis B
Original Approved Country/TerritoryUnited States
Original Approved Date2002/09/20
Country/TerritoryBelgiumUnited StatesPoland +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGilead Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcGlaxo Smith Kline Tianjin Co Ltd
Inactive CompaniesGlaxo Wellcome IncGilead Sciences IncGilead Sciences Ireland Uc +[7] 
Active IndicationsHepatitis B
Inactive IndicationsHepatitisCytomegalovirus InfectionsHepatitis B, Chronic +[5] 

Other Information

ATC CodeJ05AF08
Related LinksWikipediaDrugBankKEGG